A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

FRIDAY, June 6, 2025 (HealthDay News) — A repurposed diabetes drug can be an effective tool against fatty liver disease, a ...

A diabetes drug, dapagliflozin, has shown promise in treating fatty liver disease by reducing liver fat and scarring, ...

A recent Chinese clinical trial published in The BMJ reveals that dapagliflozin, a type 2 diabetes drug, shows promise in ...

ANSWER: Both prediabetes and diabetes are metabolic abnormalities in which the body cannot use sugar properly. There are ...

An SGLT2 inhibitor helped improve metabolic dysfunction-associated steatohepatitis (MASH) in people with or without type 2 ...

Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...

Diabetes remission was achieved in 44 and 28% of patients in the dapagliflozin and placebo groups, respectively. HealthDay News — For patients with overweight or obesity and type 2 diabetes ...

Dapagliflozin is indicated for both type 2 diabetes and heart failure. It can do the following: improve management of blood sugar and reduce the risk of hospitalization for heart failure in adults ...

Scientists at Thomas Jefferson University have made an exciting discovery that could improve the lives of many people with Type 2 diabetes. Their research shows that using two drugs ...

Reviewing the amendment protocol of the AstraZeneca's fixed dose combination (FDC) Zibotentan plus Dapagliflozin, the Subject ...